RANI — Rani Therapeutics Holdings, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1856725 ·
Last close
$0.76
Market Cap
$85.42M
52W High
$1.37
52W Low
$0.68
ADV30
1,063,463
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,708,000 | — | -8,339,000 | -7,033,000 | 51,879,000 | 9,644,000 | 16,336,000 |
| Dec 2025 | 1,461,000 | — | -8,535,000 | -10,305,000 | 58,621,000 | 18,618,000 | 17,109,000 |
| Sep 2025 | 0 | — | -7,257,000 | -5,412,000 | 10,139,000 | 4,144,000 | 22,112,000 |
| Jun 2025 | 0 | — | -10,505,000 | -6,692,000 | 16,898,000 | 10,216,000 | 26,051,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-17,062,000
Investing CF
$-27,709,000
Financing CF
$44,004,000
CapEx
$-134,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.41
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-139,613,000
Inventory
—
Receivables
$2,042,000
ST Investments
$33,759,000
EBIT TTM
$-34,190,000
Pretax Income TTM
$-36,227,000
Interest Exp TTM
$2,037,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,169,000
EBITDA
$-33,826,000
Free Cash Flow
$-3,383,000
Enterprise Value
$43,619,504
Total Cash
$43,403,000
Total Debt
$3,941,000
Shares Out
112,389,152
Trailing EPS
$-0.27
Book Value
$0.28
ROE
-240.0%
ROA
-57.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,633,000 | -38,310,000 | -29,673,000 | 58,621,000 | 17,109,000 | — | -18,714,000 |
| Dec 2024 | 1,028,000 | -49,600,000 | -30,018,000 | 36,634,000 | 33,141,000 | — | -35,496,000 |
| Dec 2023 | 0 | -66,099,000 | -33,970,000 | 57,916,000 | 32,473,000 | — | -51,236,000 |
| Dec 2022 | 0 | -63,451,000 | -30,588,000 | 108,027,000 | 34,023,000 | — | -46,515,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.22
Max Pain — expiry 2026-10-16
max pain strike: $0.50 · spot: $0.77 · call oi: 1,474 · put oi: 130Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AARD | Aardvark Therapeutics, Inc. | $85.08M | $3.90 | — |
| BMEA | Biomea Fusion, Inc. | $84.59M | $1.17 | — |
| TELO | Telomir Pharmaceuticals, Inc. | $86.66M | $1.26 | — |
| ANIX | Anixa Biosciences Inc | $84.04M | $2.47 | — |
| IBIO | iBio, Inc. | $83.96M | $1.69 | — |
News headlines (Yahoo Finance, 1h cache)
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules
2026-05-26 12:00 · Yahoo
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition
2026-05-15 20:05 · Yahoo
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
2026-05-12 20:05 · Yahoo
This Rani Therapeutics Holdings Insider Increased Their Holding By 9,754% Last Year
2026-05-08 11:11 · Yahoo
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
2026-04-09 11:00 · Yahoo
Companies Like Rani Therapeutics Holdings (NASDAQ:RANI) Are In A Position To Invest In Growth
2026-03-28 12:00 · Yahoo
Rani Therapeutics Q4 Earnings Call Highlights
2026-03-26 21:48 · Yahoo
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
2026-03-26 20:05 · Yahoo
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
2026-03-25 20:53 · Yahoo
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
2026-03-19 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.